Desoxyn

(Methamphetamine)

ApprovedSmall molecule

AAjenat

Desoxyn is one of 3 small molecule programs targeting Methamphetamine. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

FDA Application

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[3][1]

Indication

MethamphetamineCompleted

MethamphetamineApproved

Completed

Competition

Competitive Landscape

4 competitors in Methamphetamine

#DrugCompanyPhaseTrials

Desoxyn

AAjenat

Approved

6 2

Ozempic

Novo Nordisk

Phase 2

1 3

Psilocybin

COMPASS Pathways

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Recruiting

OCD

NCT05783817

Q1 2029

Phase 1Recruiting

Methamphetamine

NCT06989853

Clinical

Trials by Indication[1]

Methamphetamine6 trials

Acquisition of Responses to a Methamphetamine-associated Cue in Healthy Humans

Completed·UUniversity of Chicago·N/A·NCT02323048·90 enrolled

Study of Pomaglumetad and Methamphetamine

Terminated·UUniversity of California, Los Angeles·Phase 1·NCT03106571·19 enrolled

Behavioral Effects of Drugs (Inpatient): 40 [Methamphetamine, Methylphenidate, Duloxetine]

Completed·CCraig Rush·Phase 1·NCT04178993·8 enrolled

Show 3 more trials

Effect of Methamphetamine on Residual Latent HIV Disease Study

Completed·UUniversity of California, San Francisco·Phase 4·NCT03825536·14 enrolled

Methamphetamine and Troriluzole

Recruiting·WWilliam Stoops·Phase 1·NCT06989853·40 enrolled

Mirtazapine and Methamphetamine Drug-drug Interaction Study

Completed·SSan Francisco Department of Public Health·Phase 1·NCT04614584·15 enrolled

Methamphetamine Abuse3 trials

Pilot Study of Entacapone for Methamphetamine Abuse

Completed·OOregon Health and Science University·Phase 1·NCT02058966·29 enrolled

Targeting GABA and Opioid Systems for a Pharmacotherapy for Methamphetamine Abuse

Completed·UUniversity of Kentucky·Phase 1·NCT01967381·24 enrolled

Buspirone as a Candidate Medication for Methamphetamine Abuse

Completed·UUniversity of Kentucky·Phase 1·NCT01843205·9 enrolled

Drug2 trials

Effect of Stimulant Drugs on Social Perception

Completed·UUniversity of Chicago·Phase 1·NCT03790618·36 enrolled

Drugs Brain and Behavior (DDP)

Completed·UUniversity of Chicago·Phase 1·NCT04642820·138 enrolled

Function2 trials

Brain Function and EEG

Completed·UUniversity of Chicago·Phase 1·NCT05003076·40 enrolled

Effects of Stimulants on Behavioral and Neural Markers of Social Motivation, Ability, and Neural Markers of Social Function

Completed·UUniversity of Chicago·Phase 1·NCT05379959·43 enrolled

OCD1 trial

MDMA-Assisted CBT for OCD (MDMA-CBT4OCD Study)

Recruiting·CCarolyn Rodriguez·Phase 2·NCT05783817·40 enrolled

1 more indication

Methamphetamine Intoxication1 trial

A Phase 2 Single-Dose Study to Evaluate Safety and Efficacy of CS-1103 in Participants With Methamphetamine Use Disorder Not Seeking Treatment Receiving a Single Dose of Methamphetamine

Recruiting·CClear Scientific, Inc.·Phase 2·NCT06721494·40 enrolled

Regulatory

FDA Approval Timeline[4]

Jan 1, 1982

DESOXYN

NDA NDA005378

Sources

References

[1]
ClinicalTrials.gov — 15 trial records for Methamphetamine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Methamphetamine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Methamphetamine. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA005378). U.S. Food & Drug Administration.
[5]
SEC EDGAR — Ajenat company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: AAjenat

Desoxyn

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q1 2029

Trials by Indication[1]

Methamphetamine6 trials

Methamphetamine Abuse3 trials

Drug2 trials

Function2 trials

OCD1 trial

Methamphetamine Intoxication1 trial

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Related News